Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Leukemia

  Free Subscription


18.05.2026

1 Am J Clin Pathol
2 Ann Hematol
1 Biochem Biophys Res Commun
1 Biochem Pharmacol
6 Blood
11 Br J Haematol
2 Cancer
1 Cancer Chemother Pharmacol
1 Genes Chromosomes Cancer
4 Int J Hematol
2 Leuk Lymphoma
1 Leuk Res
1 Leukemia
1 PLoS Med


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. AMADOR C, Poveda JC, Mohammed I, Bouska A, et al
    Real-time diagnosis of adult T-cell leukemia/lymphoma using HBZ RNA in situ hybridization.
    Am J Clin Pathol. 2026;165:aqag030.
    PubMed         Abstract available


    Ann Hematol

  2. NASSEREDDINE S, Feng Y, Selep J, El Chaer F, et al
    Impact of diagnosis-to-treatment interval on the outcome of patients with acute myeloid leukemia.
    Ann Hematol. 2026 May 9. doi: 10.1007/s00277-026-07052.
    PubMed         Abstract available

  3. NAKAO F, Shima T, Takigawa K, Semba Y, et al
    Gilteritinib response in acute myeloid leukemia harboring a rare FLT3 juxtamembrane domain mutation with subsequent clonal evolution.
    Ann Hematol. 2026 May 9. doi: 10.1007/s00277-026-07061.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  4. MURATANI T, Iwashima K, Sakamoto F, Ishibashi R, et al
    Differential roles of ATM and Chk2 in cold atmospheric helium plasma-induced cell death in Molt-4 human leukemia cell with intact or reduced p53 expression.
    Biochem Biophys Res Commun. 2026;821:153843.
    PubMed         Abstract available


    Biochem Pharmacol

  5. WANG YL, Wang HL, Hao YZ, Zhu QY, et al
    S-Adenosylhomocysteine hydrolase inhibitor DZ2002 promotes diabetic wound healing by regulating Macrophage-Mediated inflammation through the mixed lineage leukemia 1-H3K4me3 axis.
    Biochem Pharmacol. 2026;250.
    PubMed         Abstract available


    Blood

  6. GAMBACORTI-PASSERINI C
    Circular RNA in chronic myeloid leukemia.
    Blood. 2026;147:2285-2286.
    PubMed        

  7. BOISSEL N, Huguet F, Leguay TT, Hunault M, et al
    Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.
    Blood. 2026 Apr 24:blood.2026033309. doi: 10.1182/blood.2026033309.
    PubMed         Abstract available

  8. UCKELMANN HJ, Gadrey JY, Brunetti L
    Nuclear transcriptional condensates as drivers and therapeutic targets in NPM1-mutated AML.
    Blood. 2026;147:2291-2297.
    PubMed         Abstract available

  9. PAPAIOANNOU D, Urs AP, Buisson R, Petri A, et al
    circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias.
    Blood. 2026;147:2375-2387.
    PubMed         Abstract available

  10. LIU Y, Jiang H, Liu J, Stuani L, et al
    DHODH as a targetable metabolic Achilles' heel for chemotherapy-resistant B-ALL.
    Blood. 2026;147:2328-2343.
    PubMed         Abstract available

  11. VALLELONGA V, Gandolfi F, Zampini M, Riva E, et al
    PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression.
    Blood. 2026;147:2358-2374.
    PubMed         Abstract available


    Br J Haematol

  12. KIM DH, Park SY, Cho H, Byun JM, et al
    Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.
    Br J Haematol. 2026;208:1724-1733.
    PubMed         Abstract available

  13. GROLL AH, Cesaro S, Alten J, Attarbaschi A, et al
    Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
    Br J Haematol. 2026;208:1846-1849.
    PubMed         Abstract available

  14. YAMAMOTO C, Yamaguchi T, Honda S, Tominaga R, et al
    Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:1679-1691.
    PubMed         Abstract available

  15. CLAUDIANI S, Metelli S, Khan A, Hannah G, et al
    Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.
    Br J Haematol. 2026;208:1660-1668.
    PubMed         Abstract available

  16. MCILROY G, Carpenter B, Hough R, James B, et al
    Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.
    Br J Haematol. 2026;208:1745-1757.
    PubMed         Abstract available

  17. COSTA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.
    Br J Haematol. 2026;208:1669-1678.
    PubMed         Abstract available

  18. SCOTT AP, Lo A, Xia Y, Thompson K, et al
    Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.
    Br J Haematol. 2026;208:1692-1703.
    PubMed         Abstract available

  19. COWELL JK, Fang X, Mori SF, Hu T, et al
    An oncogenic, truncated FGFR1 variant cooperates with SPFQ/NONO to regulate gene transcription in FGFR1-driven leukaemia.
    Br J Haematol. 2026;208:1564-1571.
    PubMed         Abstract available

  20. KALAMPALIKA F, Jimenez-Pompa A, Sanchez-Lanzas R, Patel B, et al
    Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:1572-1583.
    PubMed         Abstract available

  21. GEORGE A, Rolf E, Domeradzka M, Ribeiro S, et al
    Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.
    Br J Haematol. 2026;208:1584-1595.
    PubMed         Abstract available

  22. ALLSUP DJ, Cairns DA, Samy EF, Duley L, et al
    Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.
    Br J Haematol. 2026;208:1596-1607.
    PubMed         Abstract available


    Cancer

  23. LUO XH, Tang NN, Wang L, Zhu Y, et al
    A venetoclax-cytarabine-based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia.
    Cancer. 2026;132:e70432.
    PubMed         Abstract available

  24. AUBREY BJ, Fathi AT
    Defining a role for venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemia.
    Cancer. 2026;132:e70445.
    PubMed        


    Cancer Chemother Pharmacol

  25. VERHAGEN NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, et al
    Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2026;96:47.
    PubMed         Abstract available


    Genes Chromosomes Cancer

  26. TU J, Wang H, Wang Y, Zhou J, et al
    Novel Fusion Gene Transcripts and Targetable Mutations in High-Risk B-ALL With Exceptional Response to Venetoclax-Based Therapy.
    Genes Chromosomes Cancer. 2026;65:e70134.
    PubMed         Abstract available


    Int J Hematol

  27. JAYASWAL RP, Badyal RK, Ranawat RK
    Letter comments on: "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".
    Int J Hematol. 2026 May 13. doi: 10.1007/s12185-026-04226.
    PubMed        

  28. KATSUKI K, Miyazaki T, Komaki M, Saigusa Y, et al
    Personalized multivariable clinical prognostic model for patients with acute myeloid leukemia receiving intensive chemotherapy.
    Int J Hematol. 2026 May 12. doi: 10.1007/s12185-026-04222.
    PubMed         Abstract available

  29. YOKOYAMA H, Yanada M, Mizuno S, Uchida N, et al
    Prognostic factors influencing outcomes of allogeneic HCT for AML with monosomal karyotype.
    Int J Hematol. 2026;123:746-755.
    PubMed         Abstract available

  30. YOKOTA A, Munakata W, Kiguchi T, Ogawa Y, et al
    A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm.
    Int J Hematol. 2026;123:708-719.
    PubMed         Abstract available


    Leuk Lymphoma

  31. SHAO H, Dong N, Shao R, Sokol L, et al
    Flow cytometric analysis of phenotypes and naive/memory/effector T-cell subsets of T-cell large granular lymphocytic leukemia.
    Leuk Lymphoma. 2026 May 13:1-10. doi: 10.1080/10428194.2026.2667487.
    PubMed         Abstract available

  32. SALAH T, Stahl M, Bewersdorf JP
    Metabolic dysfunction-associated steatotic liver disease and acute leukemias - a literature review and future directions.
    Leuk Lymphoma. 2026;67:1221-1230.
    PubMed         Abstract available


    Leuk Res

  33. HALDER R, Singh R, Rainchwar S, Bhatnagar S, et al
    Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study.
    Leuk Res. 2026;165:108218.
    PubMed         Abstract available


    Leukemia

  34. DUCOURNEAU B, Pages A, Struski S, Decamp M, et al
    Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.
    Leukemia. 2026 May 12. doi: 10.1038/s41375-026-02973.
    PubMed         Abstract available


    PLoS Med

  35. LIAO XY, Zheng H, Fang JP, Zhou DH, et al
    Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database.
    PLoS Med. 2026;23:e1005088.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum